Expression of the nucleoside transporters hENT1 (SLC29) and hCNT1 (SLC28) in pediatric acute myeloid leukemia

Isabelle Hubeek, Richard Broekhuizen, Adrian Christopher Jaramillo, Marçal Pastor-Anglada, Gertjan J.L. Kaspers, Gerrit Jansen, Jacqueline Cloos, Godefridus J. Peters*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Cellular uptake of clinically important deoxynucleoside analogs is mediated by nucleoside transporters including the human equilibrative nucleoside transporter 1 (hENT1) and the concentrative nucleoside transporter-1 (hCNT1). These transporters are responsible for influx of cytarabine and reduced hENT1 expression is a major resistance mechanism in acute myeloid leukemia. We determined hENT1 and hCNT1 protein expression by immunocytochemistry in 50 diagnostic pediatric acute myeloid leukemia patient samples. All samples expressed hENT1 [9/43 (21%) low; 26/43 (60%) medium and 8/43 (19%) high] and hCNT1 [2/42 (5%) low; 35/42 (83%) medium and 5/42 (12%) high] at the cell membrane and cytoplasm. Statistical analysis showed a non-significant relationship between survival and transporter expression and in vitro drug sensitivity. In conclusion, the nucleoside transporters hENT1 and hCNT1 are broadly expressed in pediatric acute myeloid leukemia at diagnosis.

Original languageEnglish
JournalNucleosides, Nucleotides and Nucleic Acids
DOIs
Publication statusAccepted/In press - 1 Jan 2020

Cite this